Loading...

We've got a brand new version of Simply Wall St! Try it out

SOL Global Investments

CNSX:SOL
Snowflake Description

Fair value with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SOL
CNSX
CA$58M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

SOL Global Investments Corp. operates as an investment company with a focus on the cannabis industry in the United States. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • SOL Global Investments is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
  • SOL Global Investments has significant price volatility in the past 3 months.
SOL Share Price and Events
7 Day Returns
-7%
CNSX:SOL
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-75.9%
CNSX:SOL
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
SOL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SOL Global Investments (SOL) -7% -16.5% -47% -75.9% - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • SOL underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • SOL underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
SOL
Industry
5yr Volatility vs Market

Value

 Is SOL Global Investments undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for SOL Global Investments. This is due to cash flow or dividend data being unavailable. The share price is CA$1.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SOL Global Investments's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SOL Global Investments's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:SOL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$2.38
CNSX:SOL Share Price ** CNSX (2019-09-20) in CAD CA$1.06
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SOL Global Investments.

CNSX:SOL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:SOL Share Price ÷ EPS (both in CAD)

= 1.06 ÷ 2.38

0.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SOL Global Investments is good value based on earnings compared to the CA Pharmaceuticals industry average.
  • SOL Global Investments is good value based on earnings compared to the Canada market.
Price based on expected Growth
Does SOL Global Investments's expected growth come at a high price?
Raw Data
CNSX:SOL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SOL Global Investments, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SOL Global Investments's assets?
Raw Data
CNSX:SOL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$4.02
CNSX:SOL Share Price * CNSX (2019-09-20) in CAD CA$1.06
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:SOL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:SOL Share Price ÷ Book Value per Share (both in CAD)

= 1.06 ÷ 4.02

0.26x

* Primary Listing of SOL Global Investments.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SOL Global Investments is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess SOL Global Investments's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. SOL Global Investments has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is SOL Global Investments expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SOL Global Investments has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SOL Global Investments expected to grow at an attractive rate?
  • Unable to compare SOL Global Investments's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare SOL Global Investments's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare SOL Global Investments's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:SOL Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:SOL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:SOL Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 -52 -19 95
2018-12-31 -64 29 89
2018-09-30 -17 -97 145
2018-06-30 -12 -28
2018-03-31 0 -8 -26
2017-12-31 0 -6 -19
2017-09-30 -5 -15
2017-06-30 -3 -3
2017-03-31 -2 -3
2016-12-31 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if SOL Global Investments is high growth as no earnings estimate data is available.
  • Unable to determine if SOL Global Investments is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:SOL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from SOL Global Investments Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:SOL Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 2.38
2018-12-31 2.81
2018-09-30 5.86
2018-06-30 -1.45
2018-03-31 -1.60
2017-12-31 -0.80
2017-09-30 -0.82
2017-06-30 -0.23
2017-03-31 -0.22
2016-12-31 -1.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if SOL Global Investments will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether SOL Global Investments is trading at SOL Global Investments'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. SOL Global Investments's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. SOL Global Investments's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess SOL Global Investments's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SOL Global Investments has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has SOL Global Investments performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SOL Global Investments's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SOL Global Investments has delivered over 20% year on year earnings growth in the past 5 years.
  • SOL Global Investments has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • SOL Global Investments has become profitable in the last year making it difficult to compare the CA Pharmaceuticals industry average.
Earnings and Revenue History
SOL Global Investments's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SOL Global Investments Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:SOL Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -52.39 94.99 28.12 2.68
2018-12-31 -64.09 88.78 23.37 3.44
2018-09-30 -16.79 144.61 18.07 3.39
2018-06-30 -27.64 14.62 3.36
2018-03-31 0.14 -25.79 12.54 3.14
2017-12-31 0.06 -18.99 6.12 2.83
2017-09-30 -15.49 3.01 2.38
2017-06-30 -3.37 1.61 1.72
2017-03-31 -2.74 1.64 1.04
2016-12-31 -2.30 1.76 0.46
2016-03-31 -2.87 2.86
2015-03-31 -1.18 1.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • SOL Global Investments made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • SOL Global Investments used its assets more efficiently than the CA Pharmaceuticals industry average last year based on Return on Assets.
  • It is difficult to establish if SOL Global Investments improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SOL Global Investments's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SOL Global Investments has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is SOL Global Investments's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SOL Global Investments's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SOL Global Investments is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SOL Global Investments's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SOL Global Investments's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 67.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SOL Global Investments Company Filings, last reported 5 months ago.

CNSX:SOL Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 189.16 0.58 10.04
2018-12-31 192.31 0.00 51.74
2018-09-30 249.23 0.00 285.77
2018-06-30 26.75 0.00 24.43
2018-03-31 28.87 0.00 32.16
2017-12-31 6.56 0.00 9.74
2017-09-30 10.97 0.00 10.03
2017-06-30 12.78 0.00 11.90
2017-03-31 0.80 0.00 1.09
2016-12-31 -1.01 0.35 0.04
2016-03-31 0.52 0.00 0.22
2015-03-31 0.67 0.00 0.80
  • SOL Global Investments's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if SOL Global Investments's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on SOL Global Investments's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess SOL Global Investments's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SOL Global Investments has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is SOL Global Investments's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SOL Global Investments dividends.
If you bought CA$2,000 of SOL Global Investments shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SOL Global Investments's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SOL Global Investments's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:SOL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SOL Global Investments has not reported any payouts.
  • Unable to verify if SOL Global Investments's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SOL Global Investments's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SOL Global Investments has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SOL Global Investments's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SOL Global Investments afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SOL Global Investments has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of SOL Global Investments's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brady Cobb
TENURE AS CEO 0.9 years
CEO Bio

Mr. Brady Cobb has been an Interim Chairman of SOL Global Investments Corp. since September 4, 2019 and its Chief Executive Officer since October 3, 2018. He has been a Director of SOL Global Investments Corp. since July 26, 2018. Mr. Cobb is an attorney, registered lobbyist, and consultant based in South Florida. He has emerged as a leading voice in the blooming medical cannabis industry in the United States and has been instrumental to the marketplaces transition from legal and regulatory uncertainty to sensible and long overdue federal legislative policy reforms that will provide stability and long overdue institutional growth opportunities to the medical cannabis space. As an attorney, he focuses his practice on state and federal lobbying and policy making, the development of efficient and reasonable regulatory systems and related compliance, complex license transfer/change of ownership transactions, capital markets transactions and compliance/shareholder disclosure issues with the TSX, CSE and Nasdaq. Prior to forming his own firm, He was a director at Tripp Scott, P.A. in Fort Lauderdale, Florida which is a nationally recognized law firm that specializes in governmental relations, business law, and complex business litigation.

CEO Compensation
  • Insufficient data for Brady to compare compensation growth.
  • Insufficient data for Brady to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure of the SOL Global Investments management team in years:

1
Average Tenure
  • The average tenure for the SOL Global Investments management team is less than 2 years, this suggests a new team.
Management Team

Brady Cobb

TITLE
Interim Chairman & CEO
TENURE
0.9 yrs

Peter Liabotis

TITLE
Chief Financial Officer
AGE
49
TENURE
1 yrs

Adam Wilks

TITLE
Chief Operating Officer
TENURE
0.1 yrs

Maghsoud Dariani

TITLE
Chief Scientific Officer
AGE
66
TENURE
2 yrs

Michael Barnes

TITLE
Chief Medical Officer
TENURE
1.6 yrs

Micheal Bondurant

TITLE
Chief Strategy Officer
TENURE
0.1 yrs

Paul Norman

TITLE
Chief Executive Officer of HeavenlyRx
Board of Directors

Brady Cobb

TITLE
Interim Chairman & CEO

Bart Oates

TITLE
Member of Scientific and Advisory Board

Thomas Zimmerman

TITLE
Member of Scientific and Advisory Board

Peter Levy

TITLE
Member of Scientific & Advisory Board

Roger Rai

TITLE
Director
AGE
50
TENURE
1.4 yrs

Rob Reid

TITLE
Director
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
10. Apr 19 Buy Brady Cobb Individual 05. Apr 19 05. Apr 19 239,414 CA$4.00 CA$957,656
04. Oct 18 Sell Rajiv Rai Individual 03. Oct 18 03. Oct 18 -15,000 CA$5.00 CA$-75,000
X
Management checks
We assess SOL Global Investments's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SOL Global Investments has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Imagine Owning SOL Global Investments (CNSX:SOL) And Wondering If The 18% Share Price Slide Is Justified

During the last year SOL Global Investments grew its earnings per share, moving from a loss to a profit. … CNSX:SOL Past and Future Earnings, June 8th 2019 It's good to see that there was some significant insider buying in the last three months. … A Different Perspective While SOL Global Investments shareholders are down 18% for the year, the market itself is up 0.7%.

Simply Wall St -

Should SOL Global Investments Corp. (CNSX:SOL) Be Your Next Stock Pick?

Today I've chosen to put the spotlight on SOL Global Investments Corp. … is a company that has been able to sustain great financial health, trading at an attractive share price. … report on SOL Global Investments here

Simply Wall St -

Company Info

Description

SOL Global Investments Corp. operates as an investment company with a focus on the cannabis industry in the United States. The company was formerly known as Scythian Biosciences Corp. and changed its name to SOL Global Investments Corp. in October 2018. SOL Global Investments Corp. is based in Toronto, Canada.

Details
Name: SOL Global Investments Corp.
SOL
Exchange: CNSX
Founded:
CA$57,586,641
54,327,020
Website: http://solglobal.com
Address: SOL Global Investments Corp.
100 King Street West,
Suite 5600,
Toronto,
Ontario, M5X 1C9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX SOL Common Shares Canadian National Stock Exchange CA CAD 08. Aug 2017
OTCPK SOLC.F Common Shares Pink Sheets LLC US USD 08. Aug 2017
DB 9SB Common Shares Deutsche Boerse AG DE EUR 08. Aug 2017
Number of employees
Current staff
Staff numbers
0
SOL Global Investments employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:59
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/29
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.